http://rdf.ncbi.nlm.nih.gov/pubchem/patent/MY-183331-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e8432ebff5a06ee8a6ffec8cc7611fbd
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-04
filingDate 2009-03-02-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dd3388e844d9a226c0298de500ca94e7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_76867640980e141631edec827824364c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c2572f863fab7542c78b11d0cf87fa0b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0331ea522981e17e5b76d19dd84d262a
publicationDate 2021-02-18-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber MY-183331-A
titleOfInvention Crystal form of phenylamino pyrimidine derivatives
abstract The present invention relates to a particular form of the (3,5-bis trifluoromethyl)-N-[4- methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide (formula I), processes for the preparation thereof, pharmaceutical compositions containing this crystal form, and their use as anti tumor agent in humans. The compound of formula I, also known as AN-019, is: Formula-I Development code: AN-019
priorityDate 2008-03-04-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11643997
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11562629
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID414041199
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID421814382

Total number of triples: 19.